StockTipsArenaBeta

BUY Shilpa Medicare Limited — Anuj Gupta

BUYShilpa Medicare Limited
Shilpa Medicare share price target & all analyst calls

byAnuj GuptaHorizon: NA (inferred 1–3 months)30 Jun 2026via CNBC Awaaz.

Entry₹600Stated
Target₹650
Total upside +8.33% (call closed)
Stop loss₹578-3.67% risk
Exit₹5781 Jul 2026, 12:07 pm
Stop-loss hit-3.67%
Follow Anuj Gupta for new callsGet alertsWatch SHILPAMED for new buy/sell callsGet alertsSee 45 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Jun 2026
4 supporting1 neutral0 opposing
Supports the BUY call (4)

Shilpa Medicare's subsidiary, Shilpa Biologicals, has entered into a co-development and supply agreement with Orion Corporation, Finland.

NSE · Press Release·30 Jun · today

(opens in new tab)

1 advisor has an active long-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·30 Jun · today

Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Ltd, entered into a settlement agreement with M/s Sartorius Stedim India Pvt Ltd.

BSE · Company Update·24 Jun · 5d ago

(opens in new tab)

Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare Ltd, has commissioned a new Antibody Drug Conjugate (ADC) GMP Manufacturing Facility.

NSE · Press Release·24 Jun · 6d ago

(opens in new tab)
Neutral / worth noting (1)

Shilpa Biocare Private Limited, a subsidiary of Shilpa Medicare Limited, intends to form a strategic equity partnership in Gate2Brain.

BSE · Company Update·3 Jun · 4w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Shilpa Medicare

All analyst calls on Shilpa Medicare

More from Anuj Gupta

Every call and its outcome